Research Signal – Source date 2026-01-29
Walking, rising from a chair, or staying balanced can become harder as people age. These changes are often discussed as separate problems of muscle weakness, joint pain, or falls. A review published January 29, 2026, brings them together through a possible shared contributor: chronic, low-grade inflammation associated with aging, often called “inflammaging.” It asks whether this biology might help explain mobility loss, and whether signs of it could help identify risk early enough to act.
The review draws on different kinds of evidence, including biological studies, longitudinal observations, human exercise and rehabilitation findings, and animal treatment research. Together they offer a picture of how inflammation may affect movement and what might help preserve function. They do not amount to one test showing that screening for inflammation and then treating the people flagged will prevent future disability.
How a cell’s stress response can spread
One proposed contributor is cellular senescence. Senescent cells have stopped dividing, often after stress or damage, but remain metabolically active. They can release a mixture of inflammatory cytokines, chemokines, and growth factors known as the senescence-associated secretory phenotype, or SASP.
These secretions can affect the cell that released them and neighboring cells. In the first case, signaling can reinforce the senescent state; in nearby tissue, it can prompt further senescence and inflammatory responses. The review describes a feedback loop in which senescent cells release SASP factors, inflammation encourages further cellular dysfunction, and the resulting environment sustains more senescence. The transcriptional pathway NF-κB is among the regulators discussed, with IL-1α described as an upstream influence on SASP gene expression.
Aging immune systems may add to the loop. The review describes immunosenescence, or age-related changes in immune function, that can make it harder to clear damaged and senescent cells. It also discusses altered macrophage function and changes involving T and B cells, alongside inflammatory molecules such as IL-6, TNF-α, and IL-1β. These mechanisms help explain how a persistent inflammatory environment might develop; by themselves, they do not show how much any one pathway contributes to an individual’s walking ability.
Mobility depends on more than muscle
Inflammation may affect movement through several tissues, each with a different consequence. In skeletal muscle, age-related stress and inflammation can affect satellite cells, which help repair and regenerate muscle. The review describes increased senescence markers in these cells and reduced capacity to proliferate. Inflammatory cytokines may also interfere with muscle protein synthesis, a route that could contribute to sarcopenia, the loss of muscle strength and function associated with aging.
Joints create another route. The review connects inflammaging with changes to cartilage integrity and synovial fluid function, which can accelerate osteoarthritis and reduce flexibility. It reports associations between higher IL-6 and CRP levels and osteoarthritis progression and pain severity; in people with knee osteoarthritis, TNF-α receptor expression and CRP levels are associated with greater pain and reduced mobility. Inflammation also contributes to bone resorption in the review’s account, potentially weakening bone and increasing fracture risk.
Balance and coordination involve the nervous system as well as muscles and joints. The review describes inflammatory effects on motor neurons and neuromuscular junctions, where nerve signals meet muscle fibers. Disruption in these systems can impair postural control and coordination, increasing the risk of falls. Pain and weakness can also reduce physical activity. Less movement may then feed into further functional loss, a cycle the review calls “inflamm-inactivity.”
These are connected possibilities, not interchangeable measures of one condition. Someone’s mobility can be limited by pain, weakness, balance changes, or a combination. That matters when interpreting an inflammation marker: a value linked with later difficulty does not by itself reveal which part of movement is changing or what intervention would help.
What risk markers can—and cannot—tell us
The review summarizes longitudinal findings in which inflammation measured earlier in life was associated with slower walking or functional decline later. It cites studies linking elevated midlife high-sensitivity C-reactive protein (hs-CRP) with slower gait in later life, including an association reported independently of race and socioeconomic status. Other cited work connects inflammatory and senescence-related markers with future mobility limitations. In the LIFE Study, baseline plasma markers of cellular senescence predicted incident and persistent mobility disability over 24 months; the review reports reductions in these markers and slower functional decline among participants with higher physical activity.
Such observations make inflammation a candidate early warning sign, not a proven screening-and-treatment pathway. An association can help identify patterns across groups, but it cannot establish that measuring a marker, assigning a treatment from its result, and following that treatment will prevent disability. The review does not provide a unified estimate for that full sequence.
Functional checks provide a more direct view of what a person can do. Gait speed, chair-rise tests, and reports of difficulty moving can capture changes in everyday capacity. The review also discusses digital mobility outcomes and models that combine demographic, clinical, and functional information. These approaches may help characterize risk and distinguish mobility trajectories, while biomarkers add information about biological processes. Neither type of measure alone determines which treatment is appropriate.
Exercise findings focus on function
The review describes regular physical activity as a foundational strategy for musculoskeletal health and lower systemic inflammation. It summarizes exercise research in which aerobic activity and resistance training support strength, balance, flexibility, bone density, and joint integrity. A cited review and meta-analysis of randomized trials found that regular exercise, particularly isokinetic training, reduced CRP, IL-6, and TNF-α among people with musculoskeletal pain, alongside improvements in pain and function.
Rehabilitation and physical therapy offer structured ways to begin or adapt movement. The review cites a randomized trial in which a structured rehabilitation program improved gait speed and mobility in older adults, including people with slower baseline gait speeds. These findings concern measured functional outcomes as well as inflammatory markers; they are intervention evidence, separate from studies that associate a marker with later risk.
Weight management may be part of care for obesity-related mobility loss, but the review also describes findings that help clarify the role of movement itself. In a cited meta-analysis involving people with class II and III obesity, combined aerobic and resistance training improved walking speed, muscular strength, and cardiovascular fitness even without weight loss. The result supports a practical point about the measured outcomes: improved movement and fitness need not depend on the scale changing. It does not imply that the same effects apply to every older adult or every cause of mobility difficulty.
Senescent-cell treatments remain a narrower story
The review discusses senolytics and senomorphics, approaches intended to remove senescent cells or alter their harmful signaling. One example comes from bone research in mice: genetic clearance of senescent cells and a drug combination of dasatinib and quercetin prevented age-related bone loss in the cited animal study. This is evidence about a specific experimental setting and bone outcome, not proof of restored walking or preserved mobility in older people.
The review’s table also places senescent-cell targeting in disease-specific contexts, including clinical studies involving osteoarthritis and rheumatoid arthritis, alongside preclinical work. Those settings do not establish a general senolytic benefit for age-related mobility decline. The treatment idea is biologically relevant to the proposed inflammation cycle, but evidence from animals and particular diseases cannot be carried over as a broad mobility treatment claim.
How earlier warning could protect mobility
Earlier recognition of changing mobility could give clinicians and older adults more opportunity to direct effective exercise or rehabilitation toward the people most likely to benefit. In principle, combining inflammatory markers with simple functional measures could help distinguish emerging risk from established difficulty and support timely action. The practical payoff would be more years of independent movement, if marker-informed decisions improve outcomes beyond what an association alone can show and if interventions work for the people those decisions identify.
That possibility remains conditional. The review connects plausible biology, risk associations, and findings on exercise and rehabilitation, but it does not test the complete path from early warning to lasting independence. Establishing that link would determine whether inflammation measures can do more than describe risk—and whether using them changes how well people keep moving.
Key Sources
- Primary source: Exploring the nexus between inflammation and mobility through the lens of healthy aging: current scenario and future perspectives.
DOI or Journal Page · Review or Meta-Analysis · 2026-01-29
Keep exploring